{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.593","value":"0.897"},{"groupId":"OG001","spread":"1.77","value":"2.56"},{"groupId":"OG002","spread":"1.30","value":"1.85"},{"groupId":"OG003","spread":"1.52","value":"4.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who received a 300 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG000","title":"300 mg Venetoclax"},{"description":"Participants who received a 600 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG001","title":"600 mg Venetoclax"},{"description":"Participants who received a 900 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG002","title":"900 mg Venetoclax"},{"description":"Participants who received a 1200 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG003","title":"1200 mg Venetoclax"}],"paramType":"MEAN","populationDescription":"Phase 1 dose escalation and safety expansion participants with available data","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose","title":"Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax","type":"PRIMARY","unitOfMeasure":"µg/mL"}